Nagpur: Doctor, who is at the front line of the war against Covid, hopes to keep a pandemic under the examination due to the construction of anti-covid pills, falling in the level of hospitalization and death.
At the same time, they worried about creeping satisfaction between the masses and the covid protocol forgotten.
The UK has given approval for Molnupiravir anti-covid pills, while other pills, Paxlovid, have shown promising results in the human line.
Dr.
Nitin Shinde’s infectious disease said that Paxlovid, Molnupiravir and Fluvoxamine were three oral pills to be relied on in the future for Vivermectin and Fabiflu.
“All of these oral pills need to be given during the initial period of infection after that they will have the least effect, ‘” he said, pointing to the tendency in India to report late and after trying home remedies.
Dr.
Shinde said Paxlovid can be given within five days after the appearance of symptoms while Molnupiravir in two-three days.
“I have given fluvoxamine to outpatient,” he said, praising the second and third trial results of Paxlovid.
Doctor Dr.
Jay Deshmukh said Molnupiravir was part of a global strategy to eradicate illness.
“The strategy of three branches using Molnupiravir, vaccinated the children above the age of five years and began low-cost self testing now being contemplated globally,” he said.
He welcomed the development of experimental drugs that would reduce hospitalization and the severity of the disease “but the masses should not be complacent and left the Covid protocol”.
Another transmitted disease specialist, Dr.
Ashwini Taywade, said that Molnupiravir had a good virological control record.
“Pfizer Medication (Paxlovid) has a ritonavir component (used as a HIV drug) as a booster to achieve certain effects.
This combination will come with a lot of drug interactions that need to be watched before being given,” said Took that was involved by the district administration to train health staff and Government medical team.
He added that monoclonal antibodies (combination drugs) also provide promising results.
“Research has shown monoclonal antibody therapy has worked well even in vaccinated patients,” said Dr.
Taywade.
Doctor Dr.
Rajesh Atal is also called Molnupiravir and Paxlovid as a promising drug.
“Paxlovid trace data is still smaller in size but this is a protease inhibitor and stops viral replication.
This drug can be a good choice for full vaccinated patients,” said Dr.
Atal added Molnupiravir and Paxlovid acting as a virus based on RNA actions.
Efforts to develop experimental drugs provide hope, said doctor Dr.
Sunil Deshpande.
“But random clinical trials and post-marketing supervision are needed before someone can speak for their efficacy,” he said.